Results 61 to 70 of about 43,370 (253)

Abstract PD05-06: Is ERα a Tamoxifen Predictive Factor in ERα Negative Breast Cancer in Premenopausal Women?

, 2010
Background: The majority of breast cancers are hormone receptor positive, defined as estrogen receptor (ERα) and/or progesterone receptor (PR) positive. Adjuvant tamoxifen decreases the risk of recurrence and improves survival in hormone positive breast ...
A-C Källström, PE Jönsson, B Nordenskjöld, G Landberg, M Fernö, O. Stål   +5 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Increased Expression of Estrogen Receptor α-36 by Breast Cancer Oncogene IKKε Promotes Growth of ER-Negative Breast Cancer Cells

Cellular Physiology and Biochemistry, 2013
Background/Aims: The expression of estrogen receptor-α (ERα) is one of the most important diagnostic and prognostic factors of breast cancer. Recently, ERα-36 has been identified as a novel variant of ER-α.
Qihong Li, Haiyan Sun, Jingcai Zou, Cheng Ge, Kaitao Yu, Yuan Cao, Quan Hong   +6 more
doaj   +1 more source

ERα localization to early endosomes.

, 2014
(A) MCF-7 cells were co-stained with anti-ERα Sp-1 and EEA1 N-19 antibodies both in the presence and in the absence of E2 (10 nM–15 min). pc DNA flag ERα (Nessi)-transfected HeLa cells were co-stained with anti-ERα HC-20 and EEA1 H-300 antibodies both in
Valeria Pesiri (552188), Maria Marino (525018), Filippo Acconcia (208478), Pierangela Totta (231516)   +3 more
core   +1 more source

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

Progesterone receptor modulates ERα action in breast cancer.

, 2015
Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α (ERα) function and breast cancer prognosis. Here we show that PR is not merely an ERα-induced gene target, but is also an ERα-associated protein that modulates its ...
Mohammed, Hisham, Hadfield, J, Tilley, Wayne D., Stark, Rory, Launchbury, Rosalind, Rueda, OM, Rueda, Oscar M., Russell, IA, Pugh, M., Serandour, Aurelien A., Launchbury, R, Stingl, J, Hickey, T., Brown, GD, D'Santos, C, Raj, G., Robinson, J., Saadi, Amel, Tarulli, G., Mohammed, H, Brown, G., Bruna, A, Saadi, A, Menon, S., Hadfield, J., Pugh, M, Rueda, O., Russell, I. Alasdair, Silva, Grace, Menon, Suraj, Caldas, C, Tarulli, GA, Perou, CM, Raj, Ganesh V., D’Santos, Clive, Robinson, JLL, Silva, G, Serandour, A., Menon, S, Tarulli, Gerard A., Perou, Charles M., Stark, R., Bruna, A., Hickey, TE, et al., Saadi, A., Perou, C., Brown, Gordon D., Birrell, Stephen N., Bruna, Alejandra, Birrell, SN, D'Santos, C., Stark, R, Stingl, John, Caldas, Carlos, Hadfield, James, Russell, I., Launchbury, R., Mohammed, H., Tilley, WD, Silva, G., Birrell, S., Raj, GV, Robinson, Jessica L. L., Hickey, Theresa E., Carroll, Jason S., Pugh, Michelle, Carroll, JS, Serandour, AAA   +68 more
core   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Chaitanya Aduru, Akansha Chandrasekar, Kyla Blasingame, Jonathan Rosen, Jesse M. Levine, Karla Salazar, Madhuri Chilakapati, Rod Foroozan, Victoria Hardwick, Jonathan M. Yarimi, Nikita Shukla, Timothy E. Lotze, Kristen S. Fisher, Alexander J. Sandweiss   +13 more
wiley   +1 more source

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation

Non-Coding RNA, 2016
Estrogen receptor alpha (ERα) signaling pathways are frequently disrupted in breast cancer and contribute to disease progression. ERα signaling is multifaceted and many ERα regulators have been identified including transcription factors and growth factor
Adrienne K. Conger, Elizabeth C. Martin, Thomas J. Yan, Lyndsay V. Rhodes, Van T. Hoang, Jacqueline La, Muralidharan Anbalagan, Hope E. Burks, Brian G. Rowan, Kenneth P. Nephew, Bridgette M. Collins-Burow, Matthew E. Burow   +11 more
doaj   +1 more source